Upper GI 2017

Prognosis and Treatment decisions

• PD-L1 expression is rare • MSI-subtypes nearly non-existent • EBV-subtypes non-existent Checkpoint-inhibition in ESCC and EAC perhaps less effective than in lung cancer

• Her2/neu amplification/overexpressio n: about 15% Trastuzumab in Her2-positive adenocarcinoma • TP53 wildtype carcinoma: favourable prognosis? Determination of TP53 helpful?

1) PD-L1 in esophageal carcinoma – different expression pattern on mRNA and protein level; L. Tharun......and A. Quaas 2) Epithelial PD-L2 expression marks Barrett's Esophagus and Esophageal Adenocarcinoma; S. Derks..... and A. Bass 3) The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis; O. M Fisher.... and R. V Lord - „p atients with OAC and TP53 gene mutations have reduced overall survival compared with patients without these mutations, and this effect is independent of tumour stage“. 4) Radiation sensitivity in a preclinical mouse model of medulloblastoma relies on the function of the intrinsic apoptotic pathway; A.J. Crowther......and T.R Gershon

Institute of Pathology | Alexander Quaas

Gastrointestinal Cancer Group Cologne (GCGC)